A carregar...
Publicação
Development of antibody-directed therapies: quo vadis?
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 631.65 KB | Adobe PDF |
Orientador(es)
Resumo(s)
Less is more: The efficacy of antibody-drug conjugates (ADCs) for cancer therapy is traditionally associated with cleavable linkers for payload release. Evidence now suggests that simpler constructs without cleavable moieties can afford more stable and effective ADCs.
Descrição
© 2018 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Palavras-chave
Anti-tumor agents Antibody-drug conjugates Bioconjugation Drug delivery Linkers
Contexto Educativo
Citação
Angew Chem Int Ed Engl. 2018 Feb 19;57(8):2032-2034
Editora
John Wiley & Sons, Inc.